Deep learning for predicting synergistic drug combinations: State-of-the-arts and future directions

Abstract

Combination therapy has emerged as an efficacy strategy for treating complex diseases. Its potential to overcome drug resistance and minimize toxicity makes it highly desirable. However, the vast number of potential drug pairs presents a significant challenge, rendering exhaustive clinical testing impractical. In recent years, deep learning-based methods have emerged as promising tools for predicting synergistic drug combinations. This review aims to provide a comprehensive overview of applying diverse deep-learning architectures for drug combination prediction. This review commences by elucidating the quantitative measures employed to assess drug combination synergy. Subsequently, we delve into the various deep-learning methods currently employed for drug combination prediction. Finally, the review concludes by outlining the key challenges facing deep learning approaches and proposes potential challenges for future research.

Keywords

deep learning / drug combination / drug synergy / neural network

References

[1] Kim Y, Zheng S, Tang J, Jim Zheng W, Li Z, Jiang X. Anticancer drug synergy prediction in understudied tissues using transfer learning. J Am Med Inform Assoc 2021;28(1):42-51.

[2] Vitiello PP, Martini G, Mele L, et al. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. J Exp Clin Cancer Res 2021;40:1-15.

[3] Alruwaili MM, Zonneville J, Naranjo MN, et al. A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers. Cell Rep Med. 2024;5(3):101434.

[4] Neutel JM, Giles TD, Punzi H, Weiss RJ, Li H, Finck A. Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study. J Am Soc Hypertension. 2014;8(12):915-920.

[5] Giles TD, Weber MA, Basile J, et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet North Am Ed. 2014;383(9932):1889-1898.

[6] Zheng W, Sun W, Simeonov A. Drug repurposing screens and synergistic drug-combinations for infectious diseases. Br J Pharmacol 2018;175(2):181-191.

[7] Guo H, Guo M, Xia Z, Shao Z. Membrane-coated nanoparticles as a biomimetic targeted delivery system for tumour therapy. Biomater Transl. 2024;5(1):33.

[8] Kingsak M, Meethong T, Jongkhumkrong J, Cai L, Wang Q. Therapeutic potential of oncolytic viruses in the era of precision oncology. Biomater Transl. 2023;4(2):67.

[9] Azam F, Vazquez A. Trends in phase ii trials for cancer therapies. Cancers. 2021;13(2):178.

[10] Bobrowski T, Chen L, Eastman RT, et al. Synergistic and antagonistic drug combinations against SARS-CoV-2. Mol Ther. 2021;29(2):873-885.

[11] Li P, Huang C, Fu Y, et al. Large-scale exploration and analysis of drug combinations. Bioinformatics 2015:31(12):2007-2016.

[12] Li H, Li T, Quang D, Guan Y. Network propagation predicts drug synergy in cancers predict drug synergy with network propagation. Cancer Res. 2018:78(18):5446-5457.

[13] Meng F, Li F, Liu JX, Shang J, Liu X, Li Y. NEXGB: a network embedding framework for anticancer drug combination prediction. Int J Mol Sci. 2022;23(17):9838.

[14] Sidorov P, Naulaerts S, Ariey-Bonnet J, Pasquier E, Ballester PJ. Predicting synergism of cancer drug combinations using NCI-ALMANAC data. Front Chem. 2019:7:509.

[15] Öztürk H, Özgür A, Ozkirimli E. DeepDTA: deep drug–target binding affinity prediction. Bioinformatics 2018;34(17):i821-i829.

[16] Luo X. Wang L, Hu P. Hu L. Predicting Protein-Protein Interactions Using Sequence and Network lnformation via Variational Graph Autoencoder. IEEE/ACM Transactions on Computational Biology and Bioinformatics; 2023.

[17] Li Z, Song P, Li G, et al. AI energized hydrogel design, optimization and application in biomedicine. Mater Today Bio. 2024;25:101014.

[18] Bai L, Wu Y, Li G, Zhang W, Zhang H, Su J. AI-enabled organoids: construction, analysis, and application. Bioact Mater. 2024;31:525-548.

[19] Morrone JA, Weber JK, Huynh T, Luo H, Cornell WD. Combining docking pose rank and structure with deep learning improves protein–ligand binding mode prediction over a baseline docking approach. J Chem Inf Model. 2020;60(9):4170-4179.

[20] O'Shea K, Nash R. An introduction to convolutional neural networks. 2015.

[21] Vaswani A, Shazeer N, Parmar N, et al. Attention is all you need. 2017.

[22] Scarselli F, Gori M, Tsoi AC, Hagenbuchner M, Monfardini G. The graph neural network model. IEEE Trans Neural Networks. 2008;20(1):61-80.

[23] Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimitte-Forschung. 1953:3(6):285-290.

[24] Bliss Cl. The toxicity of poisons applied jointly 1. Ann Appl Biol 1939;26(3):585-615.

[25] Lavigne GJ, Montplaisir JV. Bruxism: epidemiology, diagnosis, pathophysiology, and pharmacology. In: Fricton JR, Dubner R, eds. Orofacial pain and temporomandibular disorders: advances in pain research and therapy. New York: Raven Press; 1995. pp. 387-404.

[26] Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose–response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015;13:504-513.

[27] Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.

[28] Malyutina A, Maiumder MM, Wang W, Pessia A, Heckman CA, Tang J. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. PLoS Comput Biol. 2019;15(5):e1006752.

[29] Holbeck SL, Camalier R, Crowell JA, et al. The National Cancer Institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity. Cancer Res. 2017;77(13):3564-3576.

[30] Wooten DJ, Meyer CT, Lubbock AL, Quaranta V, Lopez CF. MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery. Nat Commun. 2021;12(1):4607.

[31] Zhang H, Ek CH, Rattray M, Milo M. SynBa: improved estimation of drug combination synergies with uncertainty quantification. Bioinformatics. 2023;39(Supplement_1):i121-i130.

[32] Zheng S, Aldahdooh J, Shadbahr T, et al. DrugComb update: a more comprehensive drug sensitivity data repository and analysis portal. Nucleic Acids Res. 2021;49(W1):W174-W184.

[33] O'Neil J, Benita Y, Feldman I, et al. An unbiased oncology compound screen to identify novel combination strategies. Mol Cancer Ther. 2016;15(6):1155-1162.

[34] Liu H, Zhang W, Zou B, Wang J, Deng DL. DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy. Nucleic Acids Res. 2020:48(D1):D871-D881.

[35] Seo H, Tkachuk D, Ho C, et al. SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology. Nucleic Acids Res. 2020;48(W1):W494-W501.

[36] Shtar G, Azulay L. Nizri O, Rokach L, Shapira B. CDCDB: a large and continuously updated drug combination database. Sci Data. 2022:9(1):263.

[37] Sun X, Zhang Y, Zhou Y, et al. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Res. 2022;50(D1):D1324-D1333.

[38] Preuer K, Lewis RP, Hochreiter S, Bender A, Bulusu KC, Klambauer G. DeepSynergy: predicting anti-cancer drug synergy with deep learning. Bioinformatics. 2018;34(9):1538-1546.

[39] Kuru HL, Tastan O, Cicek AE. MatchMaker: a deep learning framework for drug synergy prediction. IEEE/ACM Trans Comput Biol Bioinf. 2021;19(4):2334-2344.

[40] Zhang P, Tu S, Zhang W, Xu L. Predicting cell line-specific synergistic drug combinations through a relational graph convolutional network with attention mechanism. Brief Bioinf. 2022;23(6):bbac403.

[41] Wang J, Liu X, Shen S, Deng L, Liu H. DeepDDS: deep graph neural network with attention mechanism to predict synergistic drug combinations. Brief Bioinf. 2022;23(1):bbab390.

[42] Wang T, Wang R, Wei L. AttenSyn: an attention-based deep graph neural network for anticancer synergistic drug combination prediction. J Chem Inf Model. 2024;64(7)2854-2862.

[43] Guo Y, Hu H, Chen W, et al. SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction. Brief Bioinf. 2024:25(2):bbae015.

[44] Hosseini SR, Zhou X. CCSynergy: an integrative deep-learning framework enabling context-aware prediction of anti-cancer drug synergy. Brief Bioinf. 2023;24(1):bbac588.

[45] Liu Q, Xie L. TranSynergy: mechanism-driven interpretable deep neural network for the synergistic prediction and pathway deconvolution of drug combinations. PLoS Comput Biol. 2021;17(2):e1008653.

[46] Yang J, Xu Z, Wu WKK, Chu Q, Zhang Q. GraphSynergy: a network-inspired deep learning model for anticancer drug combination prediction. J Am Med Inform Assoc. 2021;28(11):2336-2345.

[47] Zhang G, Gao Z, Yan C, et al. KGANSynergy: knowledge graph attention network for drug synergy prediction. Brief Bioinf. 2023;24(3):bbad167.

[48] Liu X, Song C, Liu S, Li M, Zhou X, Zhang W. Multi-way relation-enhanced hypergraph representation learning for anti-cancer drug synergy prediction. Bioinformatics. 2022;38(20):4782-4789.

[49] Wang X, Zhu H, Chen D, Yu Y, Liu Q, Liu Q. A complete graph-based approach with multi-task learning for predicting synergistic drug combinations. Bioinformatics. 2023;39(6):btad351.

[50] Wang W, Yuan G, Wan S, et al. A granularity-level information fusion strategy on hypergraphtransformer for predicting synergistic effects of anticancer drugs. Brief Bioinf. 2024:25(1):bbad522.

[51] Wang Z, Dong J, Wu L, et al. DEML: drug synergy and interaction prediction using ensemble-based multi-task learning. Molecules. 2023;28(2):844.

[52] El Khili MR, Memon SA, Emad A. MARSY: a multitask deep-learning framework for prediction of drug combination synergy scores. Bioinformatics. 2023;39(4):btad177.

[53] Zhang T, Zhang L, Payne PR, Li F. Synergistic drug combination prediction by integrating multiomics data in deep learningmodels. Methods Mol Biol. 2021;2194:223-238.

[54] Preto AJ, Matos-Filipe P, Mourão J, Moreira IS. SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning. GigaScience. 2022;11:giac087.

[55] Zhang P. Tu S. A knowledge graph embedding-based method for predicting the synergistic effects of drug combinations. In: 2022 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) IEEE: 2022. pp. 1974-1981.

[56] Tang YC, Gottlieb A. SynPathy: predicting drug synergy through drug-associated pathways using deep learning. Mol Cancer Res. 2022;20(5):762-769.

[57] Chen D, Wang X, Zhu H, et al. Predicting anticancer synergistic drug combinations based on multi-task learning. BMC Bioinf. 2023:24(1):448.

[58] Yan S, Zheng D. A deep neural network for predicting synergistic drug combinations on cancer. Interdiscip Sci. 2024;16(1):218-230.

[59] Zhang P, Tu S. MGAE-DC: predicting the synergistic effects of drug combinations through multi-channel graph autoencoders. PLoS Comput Biol. 2023;19(3)e1010951.

[60] Wang X, Zhu H, Jiang Y, et al. PRODeepSyn: predicting anticancer synergistic drug combinations by embedding cell lines with protein–protein interaction network. Brief Bioinf. 2022;23(2):bbab587.

[61] Hu J, Gao J, Fang X, et al. DTSyn: a dual-transformer-based neural network to predict synergistic drug combinations. Brief Bioinf. 2022:23(5):bbac302.

[62] Xu M, Zhao X, Wang J, et al. DFFNDDS: prediction of synergistic drug combinations with dual feature fusion networks. J Cheminform. 2023:15(1):33.

[63] Rafiei F, Zeraati H, Abbasi K, Ghasemi JB, Parsaeian M, Masoudi-Nejad A. DeepTraSynergy: drug combinations using multimodal deep learning with transformers. Bioinformatics. 2023;39(8):btad438.

[64] Li T, Shetty S, Kamath A, et al. CancerGPT for few shot drug pair synergy prediction using large pretrained language models. NPJ Digital Med. 2024;7(1):40.

[65] Edwards CN, Naik A, Khot T, Burke MD, Ji H, Hope T. SynerGPT: in-context learning for personalized drug synergy prediction and drug design. Biorxiv. 2023;p. 2007-2023.

[66] Zhao X, Xu J, Shui Y, et al, PermuteDDS: a permutable feature fusion network for drug-drug synergyprediction. J Cheminform. 2024;16(1):41.

[67] Rafiei F, Zeraati H, Abbasi K, et al. CFSSynergy: combining feature-based and similarity-based methods for drug synergy prediction. J Chem Inf Model. 2024.

[68] Gan Y, Huang X, Guo W, Yan C, Zou G. Predicting synergistic anticancer drug combination based on low-rank global attention mechanism and bilinear predictor. Bioinformatics. 2023;39(10):btad607.

[69] Li H, Zou L, Kowah JA, et al. Predicting drug synergy and discovering new drug combinations based on a graph autoencoder and convolutional neural network. Interdiscipl Sci. 2023;15(2):316-330.

[70] Torkamannia A, Omidi Y, Ferdousi R. SYNDEEP: a deep learning approach for the prediction of cancer drugs synergy. Sci Rep. 2023;13(1):6184.

[71] Zhang Q, Zhang S, Feng Y, Shi J. Few-shot drug synergy prediction with a prior-guided hypernetwork architecture. IEEE Trans Pattern Anal Mach Intell. 2023;45(8):9709-9725.

[72] Li TH, Wang CC, Zhang L, Chen X. SNRMPACDC: computational model focused on Siamese network and random matrixprojection for anticancer synergistic drug combination prediction. Brief Bioinf. 2023:24(1):bbac503.

[73] Dong Y, Chang Y, Wang Y, et al. MFSynDCP: multi-source feature collaborative interactive learning for drug combination synergy prediction. BMC Bioinf. 2024;25(1):140.

[74] Alsherbiny MA, Radwan I, Moustafa N, et al. Trustworthy deep neural network for inferring anticancer synergistic combinations. IEEE J Biomed Health Inf. 2021;27(4):1691-1700.

[75] He H, Chen G, Yu-Chian Chen C. 3DGT-DDI: 3D graph and text based neural network for drug–drug interaction pre-diction. Brief Bioinf. 2022;23(3):bbac134.

[76] Liu S, Wang H, Liu W, Lasenby J, Guo H, Tang J. Pre-training molecular graph representation with 3D geometry. In: The Tenth International Conference on Learning Representations, ICLR 2022, Virtual Event, April 25–29.

[77] Wang Y, Wang J, Cao Z, Barati Farimani A. Molecular contrastive learning of representations via graph neural networks. Nat Machine Intell. 2022:4(3):279-287.

[78] Zhou G, Gao Z, Ding Q, et al. Uni-Mol: a universal 3D molecular representation learning framework. In: The Eleventh International Conference on Learning Representations, ICLR 2023, Kigali, Rwanda, May 1–5.

[79] Thirunavukarasu AJ, Ting DS, Elangovan K, Gutierrez L, Tan TF, Ting DSW. Large language models in medicine. Nat Med. 2023:29(8):1930-1940.

[80] Schubert MC. Wick W. Venkataramani V. Performance of large language models on a neurology board-style examination. JAMA Netw Open. 2023:6(12):e2346721.

[81] Ma K, Zang X, Feng Z, et al. LLaViLo: boosting video moment retrieval via adapter-based multimodal modeling. In: Proceedings of the IEEE/CVF International Conference on Computer Vision; 2023. p. 2798-2803.

[82] Xu H, Ye Q, Yan M, et al. mPLUG-2: a modularized multi-modal foundation model across text, image and video. In: Krause A, Brunskill E, Cho K, Engelhardt B, Sabato S, Scarlett J, eds. International Conference on Machine Learning, ICML 2023, 23–29 July 2023, Honolulu, Hawaii, USA, vol. 202 of Proceedings of Machine Learning Research PMLR; 2023. pp. 38728-38748.

[83] Li J, Li D, Savarese S, Hoi SCH. BLIP-2: bootstrapping language-image pre-training with frozen image encoders and large language models. In: Krause A, Brunskill E, Cho K, Engelhardt B, Sabato S, Scarlett J, eds. International Conference on Machine Learning, ICML 2023, 23–29 July 2023, Honolulu, Hawaii, USA, vol. 202 of Proceedings of Machine Learning Research PMLR; 2023. pp. 19730-19742.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.